PTJA08 – Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity
This is the pharmaceutical Joint Assessment PTJA08 – on siponimod for the treatment of active SPMS. In January 2020, the European Commission granted marketing authorisation for Mayzent® (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS)
PTJA06 – Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant
This is the pharmaceutical Joint Assessment PTJA06 – on polatuzumab vedotin for the treatment of relapsed/refractory DLBCL. In January 2020, The European Commission granted conditional marketing authorisation for Polivy® (polatuzumab vedotin), in combination with bendamustine plus MabThera® (rituximab) (BR), for
Important Event Dates – 2020/21
We would like to confirm some dates for key EUnetHTA events throughout the remainder of JA3. Please ensure to put these in your agenda: 25-26 March, 2020 - Heads of Agencies Meeting (Spring 2020) 1-2 April, 2020 - EUnetHTA Assembly & Forum 2020 29-30 October, 2020 - Heads
OTCA22 – Final Assessment Report and related documents now available
The final assessment report and related documents for the Other Technologies Collaborative Assessment 'Point-of-care Tests (POCT): D-Dimer and Troponin' are now available for access. Troponin and D-dimer point of care tests can be used to aid the diagnosis of patients with
November 2019 Implementation Report – Now Available
EUnetHTA is pleased to announce the new Implementation Report with Appendices are now available for access. The report covers the updated use and uptake on all Joint Action 3 assessments. The report and all related documentation is available at this link, or
PTJA06 – “Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL)” final project plan now available.
The final project plan of the assessment on polatuzumab is now available. The final assessment report will be published on 13th February, 2020. Please access the final project plan at the following link: PTJA06 Final Project Plan
OTCA17 – Final Assessment Report and related documents now available
The final assessment report and related documents for the Other Technologies Collaborative Assessment 'Lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH)' are now available for access. The present assessment addressed
PTJA08 – “Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity” project plan now available.
The Final Project Plan of the assessment on siponimod is now available. The final assessment report will be published on 13th February, 2020. Please access the Final Project Plan at the following link: PTJA08 Final Project Plan
OCTA20 Final Assessment Report is now available.
We are pleased to announce that the final assessment report for OTCA20 ‘Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)’, together with the fact check comments from manufacturers and comments from external experts including the
OCTA20 Final Assessment Report is now available.
We are pleased to announce that the final assessment report for OTCA20 ‘Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)’, together with the fact check comments from manufacturers and comments from external experts including the